| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 21st December 2020 | Gillian C Ivers Read | 829 | Open or private sale | $5.68 | $4,708.72 |
| 21st December 2020 | Gillian C Ivers Read | 1,875 | Exercise of derivative | $0.00 | |
| 21st December 2020 | Lindsey Rolfe | 1,728 | Open or private sale | $5.68 | $9,815.04 |
| 21st December 2020 | Lindsey Rolfe | 3,438 | Exercise of derivative | $0.00 | |
| 15th December 2020 | Lindsey Rolfe | 14,153 | Payment by withholding | $5.11 | $72,321.83 |
| 15th December 2020 | Lindsey Rolfe | 17,241 | Exercise of derivative | $3.28 | $56,550.48 |
| 3rd December 2020 | Lindsey Rolfe | 625 | Exercise of derivative | $0.00 | |
| 3rd December 2020 | Lindsey Rolfe | 315 | Open or private sale | $4.89 | $1,540.35 |
| 3rd December 2020 | Gillian C Ivers Read | 277 | Open or private sale | $4.89 | $1,354.53 |
| 3rd December 2020 | Gillian C Ivers Read | 625 | Exercise of derivative | $0.00 |
Clovis Oncology
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Clovis Oncology, Inc. is a commercial stage biotechnology company. It engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets.
Ticker: CLVS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1466301
Employees: 484
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $261 M (61%)
Inventory, Net: $27 M (0%)
Other Assets, Current: $15 M (0%)
Assets, Current: $323 M (-11%)
Property, Plant and Equipment, Net: $13 M (-12%)
Other Assets, Noncurrent: $22 M (-6%)
Assets: $628 M (-6%)
Accounts Payable, Current: $24 M (-24%)
Accrued Liabilities, Current: $38 M (0%)
Liabilities, Current: $113 M (-15%)
Liabilities: $726 M (-14%)
Common Stock, Value, Issued: $88 Th (60%)
Common Stock, Shares, Issued: $88 M (695%)
Additional Paid in Capital, Common Stock: $2 B (12%)
Retained Earnings (Accumulated Deficit): $2 B (8%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $45 M (0%)
Stockholders' Equity (Parent): $97 M (0%)
Liabilities and Equity: $628 M (-6%)
Revenue: $40 M (-51%)
Operating Income/Loss: $83 M (-49%)
Other Income, net: $10 M (-64%)
Provision for income taxes: $36 Th (-65%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
